Sec Form 4 Filing - Bahrt Kenneth @ Oncobiologics, Inc. - 2016-05-13

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bahrt Kenneth 2. Issuer Name and Ticker or Trading Symbol Oncobiologics, Inc. [ ONS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Medical Officer (Last) (First) (Middle) C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 05/13/2016 (Street) CRANBURY, NJ08521 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/13/2016 P 2,000 A 2,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Warrants (right to buy) $ 6.6 05/13/2016 P 1,000 ( 2 ) 02/18/2017 Common Stock 1,000 $ 0 ( 1 ) 1,000 D Series B Warrants (right to buy) $ 8.5 05/13/2016 P 1,000 ( 2 ) 05/18/2018 Common Stock 1,000 $ 0 ( 1 ) 1,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bahrt Kenneth C/O ONCOBIOLOGICS, INC. 7 CLARKE DRIVE CRANBURY, NJ08521 Chief Medical Officer Signatures /s/ Lawrence Kenyon, Attorney-in-Fact 05/17/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The reported securities are included within 2,000 Units purchased by the reporting person for $6.00 per Unit. Each Unit consists of one share of common stock, one half of a Series A warrant to purchase one share of common stock and one half of a Series B Warrant to purchase one share of common stock ( 2 )The Series A Warrants and Series B Warrants will be exercisable 30 days after 5/12/16 or on such date the underwriters separate the units, whichever date is earlier.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.